2024
Novel and emerging tests for food allergy
Liu E, Eisenbarth S. Novel and emerging tests for food allergy. 2024, 698-709. DOI: 10.1016/b978-0-323-96018-2.00081-x.Peer-Reviewed Original ResearchFood allergyActivation testingSkin prick testingRisk of developmentAvailable clinical testsSkin barrier permeabilityLow predictive valueInflammatory markersPrick testingIgE testingImmunoglobulin EBarrier permeabilityAllergyPromising biomarkerPredictive valueClinical testsGenetic testingLack of testingCellular profilingMarkersWidespread useTestingImmunoglobulinBiomarkersSeverity
2023
The association of epigenetic age acceleration and depressive and anxiety symptom severity among children recently exposed to substantiated maltreatment
Zhang Z, Moeckel C, Mustafa M, Pham H, Olson A, Mehta D, Dorn L, Engeland C, Shenk C. The association of epigenetic age acceleration and depressive and anxiety symptom severity among children recently exposed to substantiated maltreatment. Journal Of Psychiatric Research 2023, 165: 7-13. PMID: 37441927, PMCID: PMC10529086, DOI: 10.1016/j.jpsychires.2023.07.007.Peer-Reviewed Original ResearchConceptsEpigenetic age accelerationSymptom severityAnxiety symptom severitySevere depressiveGreater riskAnxiety disordersStress-sensitive biomarkersAnxiety symptomsMajor risk factorAge accelerationYears of ageMultiple psychiatric disordersChild maltreatmentHorvath clockPediatric populationRisk factorsSubstantiated child maltreatmentPsychiatric disordersPromising biomarkerPredictive valueDiagnostic thresholdDepressiveChildren 8Transitory symptomsSymptomsEmerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma
Labaki C, Saliby R, Bakouny Z, Saad E, Semaan K, Eid M, Lalani A, Choueiri T, Braun D. Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma. Hematology/Oncology Clinics Of North America 2023, 37: 937-942. PMID: 37407357, DOI: 10.1016/j.hoc.2023.05.021.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMetastatic clear cell renal cell carcinomaClear cell renal cell carcinomaCell renal cell carcinomaRenal cell carcinomaSystemic therapyCell carcinomaImmunotherapy-based regimensBiomarkers of responseSystemic regimensClinical responseValid biomarkersPromising biomarkerHeterogeneous outcomesTherapyBiomarkersRegimensPatientsCarcinomaMccRCCResponseCurrent and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease
Sandokji I, Xu Y, Denburg M, Furth S, Abraham A, Greenberg J. Current and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease. Nephron 2023, 148: 1-10. PMID: 37232009, PMCID: PMC10840447, DOI: 10.1159/000530918.Peer-Reviewed Original ResearchChronic kidney diseaseCKD progressionKidney diseaseNovel biomarkersProgression of CKDLong-term adverse outcomesPediatric chronic kidney diseaseKidney function declineGlomerular filtration rateRisk of deathScreening studyCKD pathophysiologyFunction declineKidney biomarkersAdverse outcomesProgression riskFiltration rateClinical managementEarly recognitionClinical trialsPrognostic markerEarly diagnosisHigh riskClinical practicePromising biomarkerComparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas
Woodard G, Ding V, Cho C, Brand N, Kratz J, Jones K, Jablons D. Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas. Lung Cancer 2023, 180: 107211. PMID: 37121213, PMCID: PMC10900430, DOI: 10.1016/j.lungcan.2023.107211.Peer-Reviewed Original ResearchConceptsInvasive portionDriver mutationsSolid adenocarcinomaLung cancer driver mutationsNext-generation sequencingWarrants further studyLobar resectionClinical characteristicsSurgical databaseAsian patientsInvasive cancerPoor prognosisLung cancerLung lesionsInvasive componentInvasive solid tumorsNormal lungLepidicStage IPromising biomarkerSolid tumorsCancer developmentSame time periodGenes SPP1Gene expression
2022
Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions
Rodwin RL, Siddiq NZ, Ehrlich BE, Lustberg MB. Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions. Frontiers In Pain Research 2022, 3: 864910. PMID: 35360655, PMCID: PMC8963873, DOI: 10.3389/fpain.2022.864910.Peer-Reviewed Original ResearchPeripheral neuropathyChemotherapy-induced peripheral neuropathyTreatment of CIPNMultiple chemotherapeutic agentsQuality of lifeImportant clinical toolCancer survivorsTherapeutic optionsCIPNClinical practicePreventative treatmentPromising biomarkerChemotherapeutic agentsClinical implicationsClinical toolCancer diagnosisBiomarkersNeuropathyStandardized objective measuresPatientsObjective measuresTreatmentRiskChemotherapyComplications
2021
Analysis of the Applicability of microRNAs in Peripheral Blood Leukocytes as Biomarkers of Sensitivity and Exposure to Fractionated Radiotherapy towards Breast Cancer
Marczyk M, Polańska J, Wojcik A, Lundholm L. Analysis of the Applicability of microRNAs in Peripheral Blood Leukocytes as Biomarkers of Sensitivity and Exposure to Fractionated Radiotherapy towards Breast Cancer. International Journal Of Molecular Sciences 2021, 22: 8705. PMID: 34445424, PMCID: PMC8395710, DOI: 10.3390/ijms22168705.Peer-Reviewed Original ResearchConceptsBreast cancer patientsExternal beam radiotherapyCourse of radiotherapyPeripheral blood leukocytesBiomarkers of sensitivityLogistic regression modelsMultinomial logistic regression modelsFractionated RadiotherapyInter-individual variabilityCancer patientsUnivariate analysisBreast cancerCombination of miRNAsBeam radiotherapyBlood leukocytesBlood samplesPromising biomarkerTotal doseSensitive biomarkerRadiotherapyPatientsStrong inter-individual variabilityBiomarkersDoseLeukocytesPreliminary In Vivo Evidence of Reduced Synaptic Density in Human Immunodeficiency Virus (HIV) Despite Antiretroviral Therapy
Weiss JJ, Calvi R, Naganawa M, Toyonaga T, Farhadian SF, Chintanaphol M, Chiarella J, Zheng MQ, Ropchan J, Huang Y, Pietrzak RH, Carson RE, Spudich S. Preliminary In Vivo Evidence of Reduced Synaptic Density in Human Immunodeficiency Virus (HIV) Despite Antiretroviral Therapy. Clinical Infectious Diseases 2021, 73: 1404-1411. PMID: 34050746, PMCID: PMC8528400, DOI: 10.1093/cid/ciab484.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAntiretroviral therapySynaptic densityMagnetic resonance imagingMale PLWHImmunodeficiency virusUnderwent magnetic resonance imagingPositron emission tomographicCross-sectional pilotHIV neuropathogenesisViral suppressionCommon complicationSynaptic injuryNeurological impairmentDynamic biomarkersPLWHTherapeutic studiesCortical areasMotor coordinationPathological hallmarkPET scanningPromising biomarkerTherapeutic interventionsResonance imagingPegboard performance
2020
In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET
Mecca AP, Chen M, O'Dell RS, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Zhao W, Nabulsi NB, Vander Wyk B, Varma P, Arnsten AFT, Huang Y, Carson RE, van Dyck C. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. Alzheimer's & Dementia 2020, 16: 974-982. PMID: 32400950, PMCID: PMC7383876, DOI: 10.1002/alz.12097.Peer-Reviewed Original ResearchConceptsWidespread synaptic lossEarly Alzheimer's diseaseSynaptic lossAlzheimer's diseaseSynaptic vesicle glycoprotein 2AGray matter volumeMajor structural correlatePositron emission tomography (PET) imagingEmission Tomography ImagingDistribution volume ratioCerebellar reference regionNeocortical brain regionsSynaptic densityAD progressionConsistent pathologyPotential therapyMatter volumePromising biomarkerCognitive impairmentCN participantsBrain regionsDiseaseTomography imagingNormal participantsStructural correlates
2019
47 Acute Kidney Injury Diagnostics and Biomarkers
Belcher J, Parikh C. 47 Acute Kidney Injury Diagnostics and Biomarkers. 2019, 713-724.e5. DOI: 10.1016/b978-0-323-52978-5.00047-1.Peer-Reviewed Original ResearchAcute kidney injuryKidney injuryUrine outputPrognosis of AKICommon clinical conditionLong-term outcomesAppropriate clinical trialsPotential therapeutic efficacyNew therapeutic approachesMultiple potential therapiesFrank injurySerum creatinineAcute settingInjury biomarkersHigh morbidityClinical trialsDifferential diagnosisClinical conditionsEarly diagnosisTherapeutic approachesPotential therapyAnimal modelsPromising biomarkerSuch biomarkersTherapeutic efficacy
2017
Prevalence of Aflatoxin-associated TP53R249S mutation in Hepatocellular Carcinoma in Hispanics in South Texas
Jiao J, Niu W, Wang Y, Baggerly K, Ye Y, Wu X, Davenport D, Almeda J, Betancourt-Garcia M, Forse R, Stevenson H, Watt G, McCormick J, Fisher-Hoch S, Beretta L. Prevalence of Aflatoxin-associated TP53R249S mutation in Hepatocellular Carcinoma in Hispanics in South Texas. Cancer Prevention Research 2017, 11: 103-112. PMID: 29089331, PMCID: PMC5811406, DOI: 10.1158/1940-6207.capr-17-0235.Peer-Reviewed Original ResearchConceptsAdvanced fibrosisHepatocellular carcinomaCell-free DNAHCC patientsHispanic subjectsShorter overall survivalPlasma cell-free DNAAsian HCC patientsOverall survivalWorse prognosisAflatoxin exposureHigh incidenceCirrhosisHCC tumorsPromising biomarkerDietary exposureFibrosisYounger agePatientsDroplet digital PCRHispanicsSomatic mutationsFamily membersUpstream regulatorSubjectsDNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy
Nemec AA, Abriola L, Merkel JS, de Stanchina E, DeVeaux M, Zelterman D, Glazer PM, Sweasy JB. DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy. Molecular Cancer Research 2017, 15: 269-280. PMID: 28074003, PMCID: PMC5334281, DOI: 10.1158/1541-7786.mcr-16-0227-t.Peer-Reviewed Original ResearchConceptsPrognostic biomarker potentialMouse xenograft modelLung cancer cellsPoor prognosisTreatment of cancerLung cancerSpecific chemotherapyXenograft modelPromising biomarkerMouse xenograftsMutational statusCancer ResChemotherapyGermline mutationsNucleotide excision repair pathwayBiomarker potentialCancer chemotherapyCancer treatmentCarrier statusCisplatinCancer cellsTumorsCancerTreatmentCell deathPlasma Monocyte Chemotactic Protein-1 Is Associated With Acute Kidney Injury and Death After Cardiac Operations
Moledina DG, Isguven S, McArthur E, Thiessen-Philbrook H, Garg AX, Shlipak M, Whitlock R, Kavsak PA, Coca SG, Parikh CR, Consortium T. Plasma Monocyte Chemotactic Protein-1 Is Associated With Acute Kidney Injury and Death After Cardiac Operations. The Annals Of Thoracic Surgery 2017, 104: 613-620. PMID: 28223055, PMCID: PMC5588689, DOI: 10.1016/j.athoracsur.2016.11.036.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedBiomarkersCardiac Surgical ProceduresCause of DeathChemokine CCL2FemaleFollow-Up StudiesHeart DiseasesHumansIncidenceMaleOdds RatioOntarioPostoperative ComplicationsPreoperative PeriodPrognosisProspective StudiesRisk AssessmentRisk FactorsSurvival RateUnited StatesConceptsAcute kidney injuryMCP-1 levelsRisk of deathCardiac operationsChemotactic protein-1Highest tertileKidney injuryMCP-1Plasma MCP-1 levelsSevere acute kidney injuryMonocyte chemotactic protein-1High-risk patientsIschemia-reperfusion injuryPlasma MCP-1Protein 1AKI outcomesAKI riskAdjusted riskObservational cohortPrevention strategiesPromising biomarkerBiomarker endpointsTertileInjuryTranslational researchData-Independent Acquisition and Parallel Reaction Monitoring Mass Spectrometry Identification of Serum Biomarkers for Ovarian Cancer
Rauniyar N, Peng G, Lam TT, Zhao H, Mor G, Williams KR. Data-Independent Acquisition and Parallel Reaction Monitoring Mass Spectrometry Identification of Serum Biomarkers for Ovarian Cancer. Biomarker Insights 2017, 12: 1177271917710948. PMID: 28615921, PMCID: PMC5462478, DOI: 10.1177/1177271917710948.Peer-Reviewed Original Research
2013
Association of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Weidhaas J, Lee J, Slebos R, Howard J, Perez J, Gilbert J, Nallur S, Paranjape T, Garcia J, Burtness B, Forastiere A, Chung C. Association of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2013, 31: 6016-6016. DOI: 10.1200/jco.2013.31.15_suppl.6016.Peer-Reviewed Original ResearchNeck squamous cell carcinomaSquamous cell carcinomaKRAS-variantMetastatic headCell carcinomaP16/HPV statusRecurrent/metastatic headPoor progression-free survivalCisplatin resistanceHuman papillomavirus (HPV) statusProgression-free survivalTG/GGM HNSCCTumor DNA samplesHPV statusPatient demographicsHNSCC patientsClinical outcomesPoor outcomePoor prognosisPrognostic significancePredictive biomarkersClinical trialsProspective validationPromising biomarker
2011
A high-quality secretome of A549 cells aided the discovery of C4b-binding protein as a novel serum biomarker for non-small cell lung cancer
Luo X, Liu Y, Wang R, Hu H, Zeng R, Chen H. A high-quality secretome of A549 cells aided the discovery of C4b-binding protein as a novel serum biomarker for non-small cell lung cancer. Journal Of Proteomics 2011, 74: 528-538. PMID: 21262398, DOI: 10.1016/j.jprot.2011.01.011.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCellular proteomeCell lung cancerCancer secretomeLung cancerOne-dimensional gel electrophoresisA549 cellsBiomarker discoveryProteomic dataGene expressionSecretory proteinsIntracellular contaminationNovel promising biomarkerNovel serum biomarkersEnzyme-linked immunosorbent assaySecretomeProteinSerum proteomic dataClinical stagingProteomeSerum biomarkersGel electrophoresisC4BP levelsPromising biomarkerImmunosorbent assay
2008
Malignancy in Lung Transplantation: Biomarkers, Gender Differences, and Consideration of a Systems Biology Approach
Studer SM, Taioli E, Crespo M, Kaminski N. Malignancy in Lung Transplantation: Biomarkers, Gender Differences, and Consideration of a Systems Biology Approach. Transplantation 2008, 85: s69-s71. PMID: 18425041, DOI: 10.1097/tp.0b013e31816c2feb.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply